← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,458	+108	+8%	$79.4B
2	2 Danaher DHR $158B	1,303	+38	+3%	$57.5B
3	3 Novartis NVS $279B	1,088	+60	+6%	$23.4B
4	4 Illumina ILMN $41B	845	+48	+6%	$40B
5	5 Agilent Technologies A $49.1B	694	+23	+3%	$18.2B
6	6 Regeneron Pharmaceuticals REGN $80.1B	671	+27	+4%	$27.4B
7	7 Charles River Laboratories CRL $14.4B	407	+41	+11%	$5.18B
8	8 Revvity RVTY $17B	382	-17	-4%	$8.4B
9	9 Sarepta Therapeutics SRPT $1.78B	336	-9	-3%	$7.5B
10	10 Ionis Pharmaceuticals IONS $7.1B	330	+8	+2%	$6.37B
11	11 Alnylam Pharmaceuticals ALNY $30B	284	-21	-7%	$6.74B
12	12 DELISTED CATALENT, INC. CTLT	267	-10	-4%	$4.54B
13	13 Myriad Genetics MYGN $397M	264	-20	-7%	$2.22B
14	14 Qiagen QGEN $9.41B	252	+6	+2%	$4.97B
15	15 DELISTED bluebird bio BLUE	251	-37	-13%	$6.06B
16	16 Bruker BRKR $8.47B	229	+9	+4%	$3.22B
17	17 Azenta AZTA $1.63B	228	-15	-6%	$1.86B
18	18 DELISTED SANGAMO THERAPEUTICS INC SGMO	197	-20	-9%	$735M
19	19 Editas Medicine EDIT $349M	194	-5	-3%	$784M
20	20 Regenxbio RGNX $454M	183	-20	-10%	$1.26B
21	21 Precigen PGEN $2.64B	166	-4	-2%	$773M
22	22 Ultragenyx Pharmaceutical RARE $1.47B	165	-12	-7%	$2.2B
23	23 PTC Therapeutics PTCT $4.98B	164	-16	-9%	$1.67B
24	24 Arrowhead Research ARWR $8.25B	158	+26	+20%	$728M
25	25 CRISPR Therapeutics CRSP $4.86B	155	-24	-13%	$631M